相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy
Antonio Benito Porcaro et al.
UROLOGIA INTERNATIONALIS (2016)
Efficacy and tolerability of 1-and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study
Johan Braeckman et al.
ARCHIVES OF MEDICAL SCIENCE (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Nicolas Mottet et al.
EUROPEAN UROLOGY (2011)
Interest of a 6-month depot form of hormonotherapy in the treatment of advanced hormone dependent prostate cancer: Results from the 'ELIRE' observational study
I. Ouzaid et al.
PROGRES EN UROLOGIE (2011)
A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
Ulf W. Tunn
BMC UROLOGY (2011)
A 12-month clinical study of LA-2585 (45.0 MG): A new 6-month subcutaneous delivery system for Leuprolide acetate for the treatment of prostate cancer
ED Crawford et al.
JOURNAL OF UROLOGY (2006)
A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer
R Perez-Marreno et al.
CLINICAL THERAPEUTICS (2002)
分享论文
